Literature DB >> 32966799

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.

Joachim Tetteh Siaw1, Niloufar Javanmardi2, Jimmy Van den Eynden3, Dan Emil Lind1, Susanne Fransson2, Angela Martinez-Monleon2, Anna Djos2, Rose-Marie Sjöberg2, Malin Östensson4, Helena Carén5, Gunhild Trøen6, Klaus Beiske6, Ana P Berbegall7, Rosa Noguera7, Wei-Yun Lai1, Per Kogner8, Ruth H Palmer9, Bengt Hallberg10, Tommy Martinsson11.   

Abstract

High-risk neuroblastomas typically display an undifferentiated or poorly differentiated morphology. It is therefore vital to understand molecular mechanisms that block the differentiation process. We identify an important role for oncogenic ALK-ERK1/2-SP1 signaling in the maintenance of undifferentiated neural crest-derived progenitors through the repression of DLG2, a candidate tumor suppressor gene in neuroblastoma. DLG2 is expressed in the murine "bridge signature" that represents the transcriptional transition state when neural crest cells or Schwann cell precursors differentiate to chromaffin cells of the adrenal gland. We show that the restoration of DLG2 expression spontaneously drives neuroblastoma cell differentiation, highlighting the importance of DLG2 in this process. These findings are supported by genetic analyses of high-risk 11q deletion neuroblastomas, which identified genetic lesions in the DLG2 gene. Our data also suggest that further exploration of other bridge genes may help elucidate the mechanisms underlying the differentiation of NC-derived progenitors and their contribution to neuroblastomas.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALK; DLG2; ERK; NGF; SNP; TRK; genomic profiles; neuroblastoma; retinoic acid; tumor suppressor; whole-genome sequencing

Mesh:

Substances:

Year:  2020        PMID: 32966799     DOI: 10.1016/j.celrep.2020.108171

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  9 in total

1.  Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma.

Authors:  Muhammad Mushtaq; Judit Liaño-Pons; Lourdes Sainero-Alcolado; Aida Rodriguez-Garcia; Ye Yuan; Tong Liu; María Victoria Ruiz-Pérez; Susanne Schlisio; Oscar Bedoya-Reina; Marie Arsenian-Henriksson
Journal:  J Exp Clin Cancer Res       Date:  2022-07-19

Review 2.  Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.

Authors:  Anna M Wulf; Marcela M Moreno; Chloé Paka; Alexandra Rampasekova; Karen J Liu
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

Review 3.  Chromosome Imbalances in Neuroblastoma-Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future.

Authors:  Jikui Guan; Bengt Hallberg; Ruth H Palmer
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

4.  ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.

Authors:  Joanna Szydzik; Dan E Lind; Badrul Arefin; Yeshwant Kurhe; Ganesh Umapathy; Joachim Tetteh Siaw; Arne Claeys; Jonatan L Gabre; Jimmy Van den Eynden; Bengt Hallberg; Ruth H Palmer
Journal:  Nat Commun       Date:  2021-11-24       Impact factor: 14.919

5.  Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.

Authors:  Yujun Hao; Baoyu He; Liping Wu; Yamu Li; Chao Wang; Ting Wang; Longci Sun; Yanhua Zhang; Yangyang Zhan; Yiqing Zhao; Sanford Markowitz; Martina Veigl; Ronald A Conlon; Zhenghe Wang
Journal:  Nat Commun       Date:  2022-04-13       Impact factor: 17.694

6.  Inflammation suppresses DLG2 expression decreasing inflammasome formation.

Authors:  Simon Keane; Matthew Herring; Peter Rolny; Yvonne Wettergren; Katarina Ejeskär
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-02       Impact factor: 4.322

7.  A Deficiency of the Psychiatric Risk Gene DLG2/PSD-93 Causes Excitatory Synaptic Deficits in the Dorsolateral Striatum.

Authors:  Taesun Yoo; Shambhu Joshi; Sanjaya Prajapati; Yi Sul Cho; Jinkyeong Kim; Pil-Hoon Park; Yong Chul Bae; Eunjoon Kim; Soo Young Kim
Journal:  Front Mol Neurosci       Date:  2022-07-28       Impact factor: 6.261

8.  Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.

Authors:  Kaylee M Keller; Thomas F Eleveld; Linda Schild; Kim van den Handel; Marlinde van den Boogaard; Vicky Amo-Addae; Selma Eising; Kimberley Ober; Bianca Koopmans; Leendert Looijenga; Godelieve A M Tytgat; Bauke Ylstra; Jan J Molenaar; M Emmy M Dolman; Sander R van Hooff
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

9.  Silencing of AKIP1 Suppresses the Proliferation, Migration, and Epithelial-Mesenchymal Transition Process of Glioma Cells by Upregulating DLG2.

Authors:  Zhaohui Chen; Haitao Wen; Jinwei Zhang; Xin Zou; Shuihua Wu
Journal:  Biomed Res Int       Date:  2022-01-24       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.